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ABSTRACT
Portal hypertension is the most common complication of chronic liver diseases, such as cirrhosis. The increased
intrahepatic vascular resistance seen in hepatic disease is due to changes in cellular architecture and active contraction
of stellate cells. In this article, we review the historical aspects of the kallikrein-kinin system, the role of bradykinin in
the development of disease, and our main findings regarding the role of this nonapeptide in normal and experimental
models of hepatic injury using the isolated rat liver perfusion model (mono and bivascular) and isolated liver cells.
We demonstrated that: 1) the increase in intrahepatic vascular resistance induced by bradykinin is mediated by B2
receptors, involving sinusoidal endothelial and stellate cells, and is preserved in the presence of inflammation, fibrosis,
and cirrhosis; 2) the hepatic arterial hypertensive response to bradykinin is calcium-independent and mediated by
eicosanoids; 3) bradykinin does not have vasodilating effect on the pre-constricted perfused rat liver; and, 4) after
exertion of its hypertensive effect, bradykinin is degraded by angiotensin converting enzyme. In conclusion, the
hypertensive response to BK is mediated by the B2 receptor in normal and pathological situations. The B1 receptor is
expressed more strongly in regenerating and cirrhotic livers, and its role is currently under investigation.
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INTRODUCTION
The first description of isolated liver perfusion in the
scientific literature was recorded in 1855 by Claude Ber-
nard, when he was studying hepatic carbohydrate meta-
bolism:
“J’ai choisi un chien adulte, vigoureux et bien
portant, qui depuis plusiers jours était nourri
exclusivement avec de la viande, et je l’ai sac-
rifié par la section du bulbe rachidien, sept
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heures aprés un repas copieux de tripes. Aus-
sitôt l’abdomen fut ouvert, le foie fut enlevé
en évitant de blesser son tissu, et cet organe
encore tout chaud et avant que le sang êut le
temps de se coaguler dans ses vaisseaux, fut
soumis à un lavage à l’eau froide par la veine
porte. Pour cela, je pris un tube de gutta-
percha, long de 1 mètre environ et portant à
ses deux extrémités des ajustages en cuivre.
Le tube étant préalablement rempli d’eau, une
de ses extrémités fut solidement fixée au robi-
net de la fontaine du laboratoire de médicine
du Collége de France. En ouvrant le robinet,
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l’eau traversa le foie avec une grande rapid-
ité, car la force du courrant d’eau était ca-
pable, ainsi que cela fut mesuré, de soulever
une colonne de mercure à 127 centimètres de
hauteur (Bernard 1855).”
In 1948, Maurício Rocha e Silva, Wilson T. Be-
raldo, and Gastão Rosenfeld, working in the Biological
Institute of São Paulo, described a substance that, when
generated in the plasma by Bothrops jararaca venom
or trypsin, showed an important arterial hypotensive ac-
tion in cats and rabbits and stimulated guinea pig intesti-
nal and uterine musculature contraction. They named
the molecule bradykinin (BK, from Greek brady, slow
and kinesia, movement) indicating a substance that pro-
duced a slow movement of the gut (Rocha e Silva et
al. 1949). Their report follows: “In 1948, Beraldo,
Rosenfeld, and I were interested to discover whether the
venom of the B. jararaca liberated histamine from dog’s
liver as trypsin had been shown to do. The liver was
perfused with defibrinated blood through the portal vein
and the perfusates collected in the inferior vena cava
just above the diaphragm. Since dog’s blood practically
does not contain histamine or any substance stimulating
the guinea-pig gut, the perfusates were assayed directly
upon the gut after the muscle had been made insensi-
tive to the venom by desensitization. As soon as the
venom was injected in the perfusing cannula, the per-
fusates acquired enormous activity upon the guinea-pig
ileum.” (Rocha e Silva 1955).
The primary structure of bradykinin (Arg-Pro-Pro-
Gly-Phe-Ser-Pro-Phe-Arg) was elucidated at the Na-
tional Institute for Medical Research, Mill Hill, Lon-
don (Elliott et al. 1960) and it was only in 1991 that
the first kinin receptor cDNA was cloned (McEachern
et al. 1991). In 1965, Ferreira found that the Bothrops
jararaca venom contained a factor that potentiated sev-
eral pharmacological actions of BK in vivo and in vitro.
This factor was the basis for the development of the first
generation of potent pharmaceuticals (captopril) for the
treatment of arterial hypertension.
Angiotensin (hypertensin) was first described in
1939 in Argentina by Muñoz et al., and angiotensin-
converting enzyme (ACE) was later characterized from
horse plasma (Skeggs et al. 1956). The tissue conver-
sion of angiotensin I (AI) to angiotensin II (AII) was
demonstrated in Leal Prado’s Laboratory at Escola Pau-
lista de Medicina (Carlini et al. 1958) and this pioneer-
ing work was recognized later in an important review
(Vane 1974).
In 1976, we demonstrated that BK and angioten-
sins I and II produced a portal hypertensive response
in the liver, and that the liver efficiently inactivates BK
(90% from an initial dose of 19μM) and converts AI to
AII. We also verified that doses ranging from 0.17 to
0.34 nmols of AII were approximately 90% inactivated
during a single passage through the liver (Borges et al.
1976). Later we verified that AI did not induce, per se, a
portal hypertensive response, but its action was a result
of its conversion to AII and subsequent action on the AT1
receptor, primarily within the periportal zone of the liver
(Carvalho et al. 2007).
This review will summarize the hepatic response to
bradykinin in normal and experimental models of liver
disease.
CHARACTERISTICS OF THE KININ SYSTEM
AND ITS ROLE IN DISEASES
The kinin system (KS) comprises several proteins and
peptides, including precursors (kininogens), kinin-lib-
erating enzymes (pro-kallikrein), biologically active ki-
nins, and kinin-metabolizing enzymes. The kininogens
(high molecular weight kininogen, HMWK, or low mo-
lecular weight kininogen, LMWK) are multifunctional
glycoproteins synthesized by the liver (Borges and Gor-
don 1976) and other tissues (Figueroa et al. 1992);
kininogens contain the kinin sequence in its mid por-
tion and are the only precursors of the kinin peptides.
Tissue and plasma kallikreins are serine proteases that
differ from one another in their biochemical and func-
tional characteristics (Bhoola et al. 1992). Kininogens
and tissue kallikreins are expressed in many different
tissues, whereas plasma kallikrein is predominantly pro-
duced by the liver. Plasma prokallikrein is a single chain
glycoprotein synthesized and secreted by the liver; its
cleavage by factor XIIa or its fragments generates plasma
kallikrein. Its proteolytic activity is regulated by plasma
inhibitors and hepatic clearance (Borges et al. 1981,
1986, Kouyoumdjian et al. 1989). Plasma kallikrein is
primarily cleared by the liver (Borges et al. 1985); clear-
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ance is mediated by a galectin in a calcium-independent
pathway (Nagaoka et al. 2003). The hepatic removal of
tissue kallikreins (pig pancreatic and horse urinary) from
circulation involves receptor-mediated endocytosis by
C-type lectins, which were characterized as mannosyl-
and galactosyl-specific, respectively (Kouyoumdjian et
al. 1989).
In humans, plasma kallikrein forms BK from
HMWK, whereas tissue kallikreins form kallidin (Lys-
BK) from HMWK and LMWK. By contrast, both plasma
and tissue kallikrein generate BK in rodents (Bhoola
et al. 1992, Campbell 2001). The cleavage of Lys-BK
by aminopeptidase generates BK, and cleavage by car-
boxypeptidase generates des-Arg9-BK and des-Arg9Lys-
BK. Several enzymes are responsible for inactivation
and metabolism of BK; for a long period of time, inacti-
vation was attributed almost exclusively to angiotensin-
converting enzyme (ACE) from the lung, although the
liver plays an important role in BK inactivation (Prado
et al. 1975). Hepatic modulation of KS, as demon-
strated by the isolated and exanguinated perfused rat
liver model, is shown in Figure 1.
In the rat liver, the kininase metalloendopeptidase
EC 3.4.24.15 predominates over ACE and prolylendo-
peptidase (Molina et al. 1996). However, our evidence
suggests that ACE, and not EC 3.4.24.15, is the main
kininase involved in BK degradation by the liver (Gioli-
Pereira et al. 2005). Hepatic EC 3.4.24.15 cleaves BK
at the Phe5-Ser6 residue, releasing two peptides; the
BK 1-5 fragment has a protective role against the dele-
terious effects of lipopolysaccharide in rats (Morinelli
et al. 2001).
The KS has paracrine activity that is the release
of BK from HMWK. Once released, BK has a potent
effect on vascular tone: it relaxes the arterial vascula-
ture, causing hypotension, and increases portal vascular
tone, causing isolated hypertension in this area (Borges
et al. 1976).
Bradykinin acts on two types of receptors: B1 (in-
ducible) and B2 (constitutive; see Table I). Both mediate
the same action, and their differentiation was based ini-
tially on a comparison of the potency of agonists and
antagonists in several vascular preparations (Regoli et
al. 1994). The B1 receptor (B1R) responds more effi-ciently to the octapeptide des-Arg9-BK than to BK it-
self, whereas the B2 receptor (B2R) responds more effi-ciently to BK than to des-Arg9-BK. Antagonists of B1Rand B2Rs are both available: des-Arg9[Leu8]-bradykininand icatibant, a synthetic peptidomimetic (HOE-140), re-
spectively (Hall 1997).
In addition to vascular effects, BK evokes the car-
dinal signs of inflammation (pain, swelling, redness, and
heat) and is therefore characterized as a chemical medi-
ator of the inflammatory response (Rocha e Silva 1964).
BK acts near the top of the inflammatory cascade via in-
teractions with B1R and B2R on target cell membranes.Activation of BK receptors is involved in the pathogen-
esis of multiple conditions (Table II).
B2R appears to be involved in the acute inflam-matory response, whereas B1R has a role in chronicinflammatory processes (Perkins and Kelly 1993, Blais
et al. 2000, Leeb-Lundberg et al. 2005, Costa-Neto et al.
2008). B1R may also play a significant role in the devel-opment of inflammatory diseases, particularly those with
an immune etiology such as diabetes, asthma, rheuma-
toid arthritis, and multiple sclerosis (Couture et al. 2001).
In streptozotocin-induced diabetes, B2R is overexpres-sed in peripheral tissues (Couture et al. 2001, Leeb-
Lundberg et al. 2005) and, interestingly, the progression
of diabetes mellitus was prevented by [Leu8]desArg9-BK
(B1R antagonist), but not by icatibant (B2R antagonist)(Zuccollo et al. 1999).
There is direct and indirect evidence for the role of
kinins in inflammatory airway diseases. Inhalation of
BK or Lys-BK, but not des-Arg9-BK, causes bron-
chospasms in asthmatic person. Bronchoconstriction in-
duced by BK was inhibited by HOE-140 (B2R antag-onist), which confirms the involvement of B2R in BK-induced bronchospasm (Abraham et al. 2006).
In multiple sclerosis and septic shock, B1R has aprotective role, while in other conditions it produces ad-
verse effects, such as pain and inflammation (Calixto et
al. 2004, Gabra et al. 2003). Although BK is capable of
initiating the cascade of cytokine release that mediates
hyperalgesic responses, antagonists of B1R and B2R failto inhibit this response (Ferreira et al. 1993, Poole et
al. 1999). In cardiovascular and renal diseases, these ac-
tions are mediated primarily by nitric oxide (NO) and
prostaglandins.
Activation of the KS could prove beneficial due to
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Fig. 1 – The liver and vasoactive peptides: bradykinin and angiotensin II. Legend: ACE: angiotensin converting enzyme; BIE: bradykinin
inactivating enzyme; S: synthesis (Borges and Gordon 1976, Borges et al. 1981); C: clearance (Borges et al. 1985); I: inactivation (Kouyoumdjian
et al. 1984, Molina et al. 2000); A: action (Borges et al. 1976, Loureiro-Silva et al. 2001, Carvalho et al. 2007).
TABLE IVasoactive peptides: action and reaction.
A) S y s t e m i c
Peptide Effect Receptor AntagonistArterial Venous
Bradykinin/Lys-BK Vasodilatation Venoconstriction B2 HOE-140Des-Arg9-(Lys)-BK B1 des-Arg9[Leu8]BKAngiotensin II Hypertension Hypertension AT1 Losartan, irbersartanB) H e p a t i c
Peptide Effect Receptor AntagonistArterial Venous
Bradykinin/Lys-BK Hypertensive response Hypertensive response B2 HOE-140Des-Arg9-(Lys)-BK No response No response B1 —Angiotensin II
Portal vein infusion No response Hypertensive response AT1 Losartan
Hepatic artery infusion Hypertensive response Hypertensive response
its effects on angiogenesis, cardiac regeneration, and
coronary blood flow; the KS also possesses anti-throm-
botic, anti-inflammatory, and anti-apoptotic effects. It
has been demonstrated that B2R is important in reducingthe size of muscle infarction (Westerman et al. 2008).
KS activation is also related to basic pathological
processes such as ischemia (Blais et al. 2000). In hy-
poxic situations, AII-induced cardiac angiogenesis is me-
diated by increased levels of BK and B2R activation(Munk et al. 2007). In the ischemic heart, des-Arg9-BK
and BK promote protective effects, via B1R and B2R,that are due to the involvement of other mediators such
as NO, prostanoid, and endothelium-derived hyperpolar-
izing factor (EDHF) (Lagneux et al. 2003).
In renal transplantation, the incidence of primary
dysfunction and poor initial graft function appears to de-
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TABLE IIBradykinin receptors and some pathophysiological functions.
Disease Effect Receptor RAS conection
Inflammation1,2 Pro-inflammatory B1 —
Pain3,4 Hyperalgesia B1 and B2Infection (sepsis)7 KS activation: BK increase B2 —
Vascular leakage and vasodilation B1 —
Arterial vasodilatation
Metabolism
Diabetes3 Prevention of progression of B1 —
insulin-dependent diabetes
Respiratory system3 Bronchospasm in asthmatic subject B2 —
(asthma and rhinitis) (not in normal subjects)
Allergic inflammation B1
Cardio-vascular3 Hypertrophy B2 ACE inhibitorsCardiopathy B2Neurological diseases3 Increase blood-brain B2 —barrier permeability
Decrease intracranial pressure
Alzheimer’s5 Improvement of cognitive deficits B1 / B2Epilepsy6 Deleterious and protective effects B1 / B2Liver
Thrombosis9 Anti-thrombotic B2 Compensatory over-expression
(B2R knockout mice) of AT2 receptorFibrosis10 Attenuates fibrosis / B1 / B2hepatocellular damage
Other diseases3
Arthritis B2R increase B2Pre-eclampsia B2R increase in platelets B2 AT1 receptor dimerizationAngiogenesis11 Endotelial cell proliferation B2 AII/AT2Arterial hypertension4 Vasodilatation – Anti-hypertensive B2 ACE inhibitionNeoplasia3,8 Tumor growth B1 / B2 —Angiogenesis stimulation
RAS: renin-angiotensin system. 1Leeb-Lundberg et al. 2005; 2Blais et al. 2000; 3Ferreira et al. 1993; 4 Poole et al. 1999; 5Prediger et al. 2008;
6Perosa et al. 2007; 7Imamura et al. 2006; 8Costa-Neto et al. 2008; 9Schmaier 2008; 10Sancho-Bru et al. 2007; 11Westermann et al. 2008.
pend on the length of cold storage and has thus been
ascribed to injury from harvesting, cold storage, and
warm reperfusion after blood vessel reconnection; i.e.,
cold ischemia-warm reperfusion injury (IRI). Kakoki et
al. (2007) showed that both B1R and B2R protect thekidney from damage caused by IRI, including reduc-
ing DNA damage, apoptosis, morphological and func-
tional kidney changes, and mortality. Recently, Wang et
al. (2008) showed that B1R antagonism promoted downregulation of pro-inflammatory and upregulation of anti-
inflammatory molecules, representing a new therapeutic
strategy for the prevention and treatment of renal IRI.
Souza et al. (2004) demonstrated an increase in tis-
sue kallikrein activity and activation of B2R after intesti-nal IRI, demonstrating the role of B2R in the developmentof inflammation and tissue loss. Therefore, B2R antag-onists may be useful adjunct therapy for the treatment
of the severe inflammatory injuries that follow ischemia
and reperfusion of the superior mesenteric artery. B2R,but not B1R, also protects against cardiac IRI by inhibit-
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ing apoptosis and limiting ventricular remodeling (Yin et
al. 2007). The role of kinins in hepatic IRI is now under
investigation in our laboratory.
Although the KS has been related to thrombotic
risk, it was observed that B2R knock-out mice were pro-tected against arterial thrombosis, and that overexpres-
sion of the AT2 receptor had a compensatory effect(Schmaier 2008).
KS, via B2R activation, is associated with suppres-sion of reactive oxygen species production and conse-
quent prevention of renal tissue damage (Chao et al.
2007). The antifibrotic effect of B2R within the kid-ney was also demonstrated by Schanstra and co-workers
(2002), supporting the potential role of BK in the anti-
fibrotic effects of ACE inhibitors. Recently, in the uni-
lateral ureteral obstruction model of renal fibrosis, B1Rhas been found to be overexpressed, and delayed treat-
ment with an orally active nonpeptide B1R antagonistwhich blocked macrophage infiltration, leading to rever-
sal of renal fibrosis (Klein et al. 2009).
The participation of kinin receptors during sepsis
remains unclear. It is well known that B1R is induced andoverexpressed during tissue injury, following inflamma-
tory processes, and after LPS administration.
LIVER AND THE KININ SYSTEM
The liver has a very sophisticated vascular system that
plays an active role in the maintenance of hepatic func-
tion. As a key organ in the control of the internal milieu,
the liver relies on appropriate tissue perfusion to control
the composition of the blood that drains into the sys-
temic circulation. Excluding the hepatic artery and its
branches, which are responsible for only 20% to 40% of
the blood entering the liver, the intra-hepatic circulation
is maintained at very low pressure in physiological condi-
tions. The vascular tone in portal venules, sinusoids, and
hepatic venules is actively controlled by several relaxing
and contracting substances, including BK (Borges et al.
1976, Loureiro-Silva et al. 1999, 2001, Gioli-Pereira et
al. 2005, Nagaoka et al. 2006).
BK plays an important role in the control of vas-
cular tone in physiological and pathological conditions.
Both a widespread distribution throughout the vascular
system and its very short half-life in circulation (Pella-
cani et al. 1992) indicate that BK participates in vascu-
lar tone control in an autocrine/paracrine way. However,
since it can be detected in the circulation, an endocrine
mechanism of action may also be involved, particularly
in pathologic conditions such as sepsis (Weipert et al.
1988). Interestingly, BK has a dual role in the vascular
tone control: it is a potent endothelium-dependent va-
sodilator but can also cause vasoconstriction by acting
directly on vascular smooth muscle cells.
The vasodilatory effect of BK depends on endothe-
lial cells that, after stimulation, release at least 3 com-
pounds: nitric oxide, prostacyclin, and EDHF (Busse et
al. 1994, Blatter et al. 1995, Nakashima et al. 1993).
Briefly, activation of B2R located on endothelial cellsinitiates a sequence of events that results in the produc-
tion of nitric oxide and prostacyclin. These two com-
pounds migrate to adjacent smooth muscle cells and,
by activating guanylate and adenylate cyclases, increase
the intra-cellular concentration of the second messen-
gers cGMP and cAMP, respectively (Holzmann et al.
1980, Waldman and Murad 1987). These cyclic nu-
cleotides activate different mechanisms that reduce in-
tracellular calcium concentration and, ultimately, cause
smooth muscle cell relaxation. The vasodilatory effect
of EDHF was originally attributed to the activation of
smooth muscle potassium channels. More recent evi-
dence suggests that EDHF release from endothelial cells
occurs following the opening of potassium channels in
stimulated endothelial cells (Busse et al. 2002). Al-
though several putative candidates have been proposed,
the identity of EDHF remains uncertain (Villar et al.
2008). In humans, the vasodilatory effect of BK has
been demonstrated in both arteries and veins (Bönner et
al. 1992).
Most of the compounds and pathways that mediate
this BK effect are expressed in the liver and are likely
to participate in intrahepatic vascular tone control. This
is most likely to be true of intra-hepatic vessels that are
structurally similar to the vessels where the BK vaso-
dilatory effect has been demonstrated, i.e., the portal
vein, hepatic artery, and their branches (Loureiro-Silva
et al. 1999).
The vasoconstrictive effect of BK is caused by the
direct action of this peptide on vascular smooth mus-
cle. It is endothelium-independent and can, in fact, be
blunted by the presence of endothelial tissue. Although
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most of studies have shown that this BK effect is me-
diated by B2R, the participation of B1R has also beendemonstrated (Felipe et al. 2007). It seems clear that
the pivotal event in BK-induced constriction of the vas-
cular smooth muscle cell is an increase in intracellular
Ca2+ concentration, which is primarily due to increased
Ca2+ influx from the extracellular space (Bkaily et al.
1997, Dong et al. 2005, Eguchi et al. 1997). Using a
rabbit saphenous vein preparation, Eguchi et al. (1997)
demonstrated the involvement of Ca2+ release from in-
tracellular thapsigargin-sensitive storages sites and a G-
protein-mediated increase in the Ca2+ sensitivity of the
contractile apparatus. Most of the BK vasoconstriction
effect observed in different preparations has been shown
to be mediated by the release of eicosanoids (Wong et al.
1977, Barabé et al. 1979, Gioli-Pereira et al. 2005).
To study the portal hypertensive response (PHR)
to BK, we used the isolated rat liver perfusion (IRLP)
model in both monovascular (via portal vein) and bivas-
cular (via portal vein and hepatic artery) conditions, in
a hemoglobin-free medium enriched with oxygen. The
IRLP is an elegant experimental model, since the liver
integrity is maintained and changes in the intrahepatic
vascular tone can be easily detected by measuring the
perfusion pressure; perfusion pressure can be monitored
by the connection of a vertical, open, graduated (cm) col-
umn to the portal cannula between the peristaltic pump
and the liver in the monovascular perfusion (Borges et
al. 1976). In the bivascular perfusion technique, the
portal perfusion pressure is measured as described, and
the hepatic artery pressure is measured by the pressure
transducer. Using these experimental models, we have
studied the intrahepatic vascular response to several va-
soactive compounds, including BK, des-Arg9-BK, AI,
and AII, in both normal and pathologic conditions. Addi-
tionally, we have carried out in vitro studies using isolated
liver cells. Our findings are summarized in the following
paragraphs.
In recirculating monovascular liver perfusion, BK
induces a PHR that is mediated by B2R and modulatedby the NO system in normal livers as well as in livers af-
fected by inflammation, fibrosis, and cirrhosis (Loureiro-
Silva et al. 2001, Nagaoka et al. 2006). During liver
regeneration, the PHR to BK is present, although it is
decreased from day 2 until 7 when compared to days 0
and 1 (Teixeira et al. 1999). The PHR was abolished in
the presence of 6μM icatibant and, interestingly, when
this B2R antagonist was used at higher concentration
(> 120μM), portal pressure continuously increased un-
til this antagonist was removed from the circuit (Gioli-
Pereira et al. 2005).
Molar excess of captopril (ACE inhibitor) and JA-2
(EC 3.4.24.15 specific inhibitor) did not modify the PHR
to BK. However, ACE, but not EC 3.4.24.15 inhibitor,
increased the BK half-life in the liver perfusion model.
On the other hand, HOE-140 inhibited the hypertensive
action of BK but had no effect on its hydrolysis (Gioli-
Pereira et al. 2005).
The hypertensive effects on the hepatic microcircu-
lation were also studied in a bivascular rat liver perfu-
sion, performed in the anterograde mode. When BK was
injected into the arterial bed, it produced a double hemo-
dynamic effect, including both hepatic arterial and por-
tal hypertensive responses. The arterial hypertensive re-
sponse was calcium-independent and mediated by eico-
sanoids; the PHR, occurring through a distinct path-
way, was not inhibited by naproxen. On the other hand,
BK injected into the portal vein produced a portal, but
not arterial, hypertensive response. This response was
calcium-dependent and was not affected by the presence
of naproxen (Gioli-Pereira et al. 2005).
The hemodynamic effects were associated with
metabolic effects when BK was injected via the arterial
route; these effects included a decrease in oxygen con-
sumption and increase in glucose release. The metabolic
effects on oxygen consumption (in the absence of Ca2+)
and on glucose release were not altered by naproxen.
When BK reaches the liver by the venous route, the
hemodynamic effect was also associated with the meta-
bolic effects of decreased oxygen consumption and in-
creased glucose release. The effect on oxygen consump-
tion was calcium-dependent and was not affected by
naproxen. The effect on glucose release was neither cal-
cium-dependent nor affected by naproxen.
The hypertensive effect of BK on sinusoidal cells
of the periportal region is followed by ACE hydroly-
sis of the peptide, primarily in the perivenous region.
Therefore, we suggested that ACE is the main kininase
involved in hepatic BK degradation (Gioli-Pereira et
al. 2005).
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Using the indicator dilution technique to study dis-
tribution volumes and transport phenomena in the liver,
we observed that, in the steady state, BK is predomi-
nantly distributed in the extracellular space. The mean
hepatic extraction of BK (200 nmol) was 16 nmol (8%),
which is compatible with the fact that BK is rapidly hy-
drolyzed by ACE after its action on sinusoidal B2R inthe periportal region (Gioli-Pereira et al. 2005).
Due to their anatomic location and ability to con-
tract or relax in response to vasoactive mediators, endo-
thelins, AII or TXA2, and NO or CO, respectively, stel-late cells seem to be involved in the regulation of por-
tal flow (Rockey 2003). Nevertheless, Kupffer cells and
endothelial cells also contain filaments, tubules, and pro-
teins that confer upon these cells the ability to regu-
late sinusoidal diameter (McCuskey and Reilly 1993).
Using isolated liver cells, we demonstrated that sinu-
soidal cells (quiescent stellate and the fraction contain-
ing Kupffer and endothelial cells), but not hepatocytes,
respond to BK, causing a basal extracellular acidifica-
tion (microphysiometer model). This response to BK
was specific because it was blocked by HOE-140, a B2Rantagonist (Gioli-Pereira et al. 2005).
As discussed before, B1R is generally absent fromnormal tissue, but its expression can be induced in a va-
riety of cells following an inflammatory stimulus. We
extensively pursued the effect of des-Arg9-BK on the
intrahepatic vascular response. Among the experimen-
tal models that we have studied were: lipopolysaccha-
ride (classical model of induction of B1R), acute phaseinflammation (turpentine oil injection), chronic inflam-
mation (i.p. CCl4 injection up to 56 days), fibrosis (i.p.porcine serum injection), cirrhosis (bile duct ligation,
BDL), and partial hepatectomy (70% resection). des-
Arg9-BK or des-Arg9-Lys-BK did not elicit change in
the portal pressure in any of these models. In a metho-
xamine pre-constricted liver, the hypertensive effect
of BK was maintained, but no intrahepatic vascular re-
sponse to B1R agonists was observed in normal, LPS-treated, or BDL rats (Nagaoka et al. 2006). On isolated
cells, we also observed that des-Arg9-BK did not elicit
a response in hepatocyte or sinusoidal hepatic cells
(Gioli-Pereira et al. 2005).
Interestingly, in spite of the absence of intrahepatic
vascular response, B1R agonists were metabolized by
the liver of normal and LPS-treated rats at the same rate,
suggesting an efficient clearance machinery for these
kinins (Nagaoka et al. 2006).
The induction of B1R was confirmed by Westernblot in some experimental groups which were studied,
such as BDL and partial hepatectomy (Nagaoka et al.
2006). In the CCl4-ip model, there was a slight band atall different times of treatment (10, 21, and 56 days). In-
terestingly, in the BDL group, B1R expression increasedin relation to the time of progression of cirrhosis, sug-
gesting a possible role of B1R in the development of fi-brosis; this hypothesis is now under investigation. In the
partial hepatectomy group, B1R expression was observedon days 1 and 2 and disappeared on day 7, suggesting a
role in tissue remodeling (Nagaoka et al. 2006).
These results were confirmed by Sancho-Bru and
co-workers (2007), who showed that rat normal liver ex-
presses both B1R and B2R and, in addition, cirrhotic liv-ers (CCl4 induction) have an overexpression of these re-ceptors. Continuous BK infusion had a hepato-protective
and anti-apoptotic role, via reduction in hepatocellular
injury and attenuation of the progression of experimen-
tal fibrosis. They suggested that the anti-fibrotic effect of
BK infusion was probably associated with the decrease
of activated hepatic stellate cells and reduction of colla-
gen and TGF-β1 expression (Sancho-Bru et al. 2007).
In summary, BK induces an increase in the intra-
hepatic vascular resistance that is mediated by B2R andpreserved in the presence of inflammation, fibrosis, and
cirrhosis. The hepatic arterial hypertensive response
to BK is calcium-independent and mediated by eicosa-
noids, and BK does not have a vasodilatation effect on
the pre-constricted perfused rat liver. Following its hy-
pertensive effect, BK is degraded by ACE. In cirrhosis
and hepatic regeneration, B1R is overexpressed, suggest-ing a role in fibrogenesis and the tissue remodeling that
now is under investigation.
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RESUMO
Hipertensão portal é a complicação mais comum das doenças
crônicas do fígado, tais como cirrose. A resistência intravas-
cular aumentada observada na doença hepática é devida a al-
terações na arquitetura celular e contração ativa das células
estreladas. Neste trabalho revisamos aspectos históricos do
estudo do sistema calicreína-cinina e os resultados de nossos
estudos do papel deste nonapeptídeo no controle do tono vascu-
lar intra-hepático em condições normais e modelos experimen-
tais de agressão hepática usando a perfusão de fígado isolado
de rato (mono e bivascular) e células hepáticas isoladas. Nós
demonstramos que: 1) o aumento da resistência vascular intra-
hepática induzido pela bradicinina é mediado por receptores
B2, envolve a participação de células endoteliais sinusoidais e
células estreladas e não é alterada pela presença de inflamação,
fibrose ou cirrose; 2) a resposta hipertensiva induzida pela
bradicinina no sistema arterial hepático é cálcio-independente e
mediada por eicosanóides; 3) bradicinina não tem efeito dilata-
dor na circulação intra-hepática; 4) após exercer efeito vaso-
constritor intra-hepático, a bradicinina é degradada pela enzima
conversora de angiotensina. Em conclusão, a resposta hiper-
tensiva à bradicinina é mediada pelo receptor B2 em condições
normais e patológicas. Receptor B1 é expresso mais forte-
mente nos fígados em regeneração e cirróticos e seu papel está
sob investigação.
Palavras-chave: bradicinina, metabolismo hepático, hiperten-
são porta, receptores de bradicinina.
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